These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 494357)

  • 1. BOMT (6 alpha-bromo-17 beta-hydroxy-17 alpha-methyl-4-oxa-5 alpha-androstan-3-one) is not an androgen antagonist within the central nervous system.
    Clark CR; Nowell NW
    Steroids; 1979 Aug; 34(2):139-49. PubMed ID: 494357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new antiandrogen, 6alpha-bromo-17 beta-hydroxy-17 alpha-methyl-4-oxa-5 alpha-androstan-3-one.
    Boris A; Uskoković M
    Experientia; 1970 Jan; 26(1):9-10. PubMed ID: 5412314
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of antiandrogens on the binding of androgen to cytosol and nuclei of hamster sebaceous glands.
    Takayasu S
    Arch Dermatol Res; 1979 Feb; 264(1):49-54. PubMed ID: 443861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Some endocrine studies of a new antiandrogen, 6-alpha-bromo-17-beta-hydroxy-17-alpha-methyl-4-oxa-5-alpha-androstan-3-one (BOMT).
    Boris A; DeMartino L; Trmal T
    Endocrinology; 1971 Apr; 88(4):1086-91. PubMed ID: 5542403
    [No Abstract]   [Full Text] [Related]  

  • 5. Impaired lactation in female offspring of rats given the antiandrogen, BOMT, during pregnancy.
    Forsberg JG; Jacobsohn D; Schain N
    Arch Anat Microsc Morphol Exp; 1974; 63(3):239-50. PubMed ID: 4464810
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antiandrogen activity of 4 beta, 5-cyclopropane-5-beta-androstan -3-ones and their 19-acetoxy derivatives].
    Stárka L; Bicíková M; Hampl R; Joska J; Fajkos J
    Cesk Farm; 1984 Oct; 33(8):336-9. PubMed ID: 6525632
    [No Abstract]   [Full Text] [Related]  

  • 7. Action of a non-steroid anti-androgen, RU 23908, in peripheral and central tissues.
    Raynaud JP; Bonne C; Bouton MM; Lagace L; Labrie F
    J Steroid Biochem; 1979 Jul; 11(1A):93-9. PubMed ID: 385986
    [No Abstract]   [Full Text] [Related]  

  • 8. [The antiandrogen effect of gossypol and its influence on androgen receptor].
    Li FY; Wang NG; Lei HP
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1985 Feb; 7(1):53-4. PubMed ID: 3158419
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of the non-steroidal antiandrogen flutamide on neural receptor binding of testosterone and intermale aggressive behavior in mice.
    Clark CR; Nowell NW
    Psychoneuroendocrinology; 1980 Jan; 5(1):39-45. PubMed ID: 7190313
    [No Abstract]   [Full Text] [Related]  

  • 10. Binding properties of testosterone receptors in the hypothalamic-preoptic area of the adult male mouse brain.
    Clark CR; Nowell NW
    Steroids; 1979 Apr; 33(4):407-26. PubMed ID: 442132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptors in the anterior pituitary and central nervous system of the androgen "insensitive" (Tfm) rat: correlation between receptor binding and effects of androgens on gonadotropin secretion.
    Naess O; Haug E; Attramadal A; Aakvaag A; Hansson V; French F
    Endocrinology; 1976 Nov; 99(5):1295-303. PubMed ID: 991822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor binding and antiandrogenic activity of some 4,5-secoandrostanes and ring B cyclopropanoandrostanes.
    Stárka L; Hampl R; Kasal A; Kohout L
    J Steroid Biochem; 1982 Sep; 17(3):331-4. PubMed ID: 6215537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptors and the molecular basis for the action of antiadrogens in the ventral prostate.
    Tymoczko JL; Liao S
    J Reprod Fertil Suppl; 1976 Sep; (24 suppl):147-62. PubMed ID: 794465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
    Moguilewsky M; Fiet J; Tournemine C; Raynaud JP
    J Steroid Biochem; 1986 Jan; 24(1):139-46. PubMed ID: 3009970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a 5 alpha-reductase inhibitor on androgen-mediated growth of the dog prostate.
    Wenderoth UK; George FW; Wilson JD
    Endocrinology; 1983 Aug; 113(2):569-73. PubMed ID: 6872940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ; Tucker H
    Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgens regulate brain aromatase activity in adult male rats through a receptor mechanism.
    Roselli CE; Resko JA
    Endocrinology; 1984 Jun; 114(6):2183-9. PubMed ID: 6723579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antiandrogenic effects of delta 1-testolactone (Teslac) in vivo in rats and in vitro in human cultured fibroblasts, rat mammary carcinoma cells, and rat prostate cytosol.
    Vigersky RA; Mozingo D; Eil C; Purohit V; Bruton J
    Endocrinology; 1982 Jan; 110(1):214-9. PubMed ID: 7053985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4'-nitro-3'trifluoromethylisobutyranilide).
    Neri R; Florance K; Koziol P; Van Cleave S
    Endocrinology; 1972 Aug; 91(2):427-37. PubMed ID: 4264731
    [No Abstract]   [Full Text] [Related]  

  • 20. Characterization of the cytosol androgen receptor of the human prostate.
    Wilbert DM; Griffin JE; Wilson JD
    J Clin Endocrinol Metab; 1983 Jan; 56(1):113-20. PubMed ID: 6183286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.